For more information please contact:
Head of Healthcare
Michael Margolis, R.Ph
Warren Dunnavant II
Equity Capital Markets
Head of Equity
Senior Vice President
Senior Vice President
BioPharmX Corporation (NYSE: BPMX), a specialty pharmaceutical company developing products for the dermatology market, has completed an underwritten public offering of (i) an aggregate 31,489,429 Class A Units, each consisting of one share of the Company's common stock and one seven-year warrant to purchase 0.75 of a share of common stock (which equates to 75% warrant coverage) at an exercise price of $0.35 per share, at a public offering price of $0.35 per unit and (ii) 1,515 Class B Units, each consisting of one share of the Company's Series A convertible preferred stock with a stated value of $1,000 per share and convertible into shares of common stock at the public offering price of the Class A Units, together with the equivalent number of warrants (75% warrant coverage) to purchase shares of common stock at an exercise price of $0.35 per share as would have been issued in connection with a purchase of $1,000 of Class A Units based at the public offering price. Each share of Series A preferred stock is convertible into approximately 2,857 shares of common stock. The underwriters exercised the over-allotment option to purchase additional warrants to purchase 3,542,560 shares of common stock.
The gross proceeds to BioPharmX from this offering were approximately $13 million. BioPharmX intends to use the net proceeds of the offering to fund further clinical development of BPX01, as well as the ongoing expenses of our operations during such development and for working capital and general corporate purposes.
ROTH Capital Partners acted as Sole Book-Running Manager in the transaction.
About BioPharmX Corporation
BioPharmX Corporation (NYSE:BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in the health and wellness markets, including dermatology and women's health.
For more information, visit
Press Release | 11/28/16)
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit